Insulet Corp
NASDAQ:PODD

Watchlist Manager
Insulet Corp Logo
Insulet Corp
NASDAQ:PODD
Watchlist
Price: 262.93 USD 0.35% Market Closed
Market Cap: 18.4B USD
Have any thoughts about
Insulet Corp?
Write Note

Insulet Corp
Current Portion of Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Insulet Corp
Current Portion of Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Current Portion of Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
Insulet Corp
NASDAQ:PODD
Current Portion of Long-Term Debt
$42m
CAGR 3-Years
13%
CAGR 5-Years
N/A
CAGR 10-Years
27%
Becton Dickinson and Co
NYSE:BDX
Current Portion of Long-Term Debt
$2.2B
CAGR 3-Years
63%
CAGR 5-Years
11%
CAGR 10-Years
27%
Boston Scientific Corp
NYSE:BSX
Current Portion of Long-Term Debt
$1.7B
CAGR 3-Years
85%
CAGR 5-Years
5%
CAGR 10-Years
88%
Stryker Corp
NYSE:SYK
Current Portion of Long-Term Debt
$2.2B
CAGR 3-Years
361%
CAGR 5-Years
33%
CAGR 10-Years
11%
Abbott Laboratories
NYSE:ABT
Current Portion of Long-Term Debt
$1.6B
CAGR 3-Years
29%
CAGR 5-Years
5%
CAGR 10-Years
23%
Intuitive Surgical Inc
NASDAQ:ISRG
Current Portion of Long-Term Debt
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Insulet Corp
Glance View

Market Cap
18.4B USD
Industry
Health Care

Insulet Corporation is a pioneering medical device company, primarily recognized for its innovative Omnipod Insulin Management System, which revolutionizes diabetes care. Founded in 2000, Insulet has focused on developing patch pump technology that offers a seamless, tubeless insulin delivery solution for individuals with insulin-dependent diabetes. This cutting-edge product allows users to manage their insulin delivery discreetly and conveniently, enhancing their quality of life and simplifying the complex regimen of diabetes management. As the prevalence of diabetes continues to rise globally, Insulet stands at the forefront of meeting a substantial medical need, capturing a significant market share with its user-friendly technology. As an investor, understanding Insulet’s growth trajectory and market potential is essential. The company has witnessed consistent revenue growth, driven by increased adoption of its Omnipod systems, and has expanded its product portfolio to include a new generation of devices that offer even greater functionality. Insulet is also heavily investing in research and development to further innovate its offerings, positioning itself competitively in the fast-evolving diabetes care market. With strong industry partnerships and a commitment to enhancing user experience, Insulet represents not just a promising investment in healthcare technology but also a company that is fundamentally improving the lives of millions.

PODD Intrinsic Value
96.69 USD
Overvaluation 63%
Intrinsic Value
Price

See Also

What is Insulet Corp's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
42m USD

Based on the financial report for Sep 30, 2024, Insulet Corp's Current Portion of Long-Term Debt amounts to 42m USD.

What is Insulet Corp's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 10Y
27%

Over the last year, the Current Portion of Long-Term Debt growth was -16%. The average annual Current Portion of Long-Term Debt growth rates for Insulet Corp have been 13% over the past three years , and 27% over the past ten years .

Back to Top